Valuation: Strides Pharma Science Limited

Market Cap 101B 1.06B 951M 878M 794M 1.49B 1.51B 10.47B 4.18B 52.94B 3.99B 3.9B 168B P/E 2027 *
16.1x
P/E 2028 * 11.5x
Enterprise Value 101B 1.06B 951M 878M 794M 1.49B 1.51B 10.47B 4.18B 52.94B 3.99B 3.9B 168B EV / Sales 2027 *
1.74x
EV / Sales 2028 * 1.46x
Free-Float
68.12%
Yield 2027 *
0.27%
Yield 2028 * 0.27%
1 day+1.10%
1 week+7.04%
Current month-2.01%
1 month-4.68%
3 months+5.36%
6 months+4.33%
Current year+21.90%
1 week 980.4
Extreme 980.4
1,116.4
1 month 980.4
Extreme 980.4
1,174.5
Current year 768.65
Extreme 768.65
1,260.9
1 year 768.65
Extreme 768.65
1,260.9
3 years 467
Extreme 467
1,675
5 years 263.35
Extreme 263.35
1,675
10 years 263.35
Extreme 263.35
1,675
Manager TitleAgeSince
Chief Executive Officer - 01/06/2024
Director of Finance/CFO 42 01/06/2024
Chief Tech/Sci/R&D Officer - 21/11/2024
Director TitleAgeSince
Chairman 65 -
Director/Board Member - 18/05/2017
Director/Board Member 82 18/05/2017
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%+7.04%+34.83%+120.27% 1.05B
+6.31%+4.26%+67.47%+140.83% 1,148B
+1.20%+2.26%+46.66%+86.13% 652B
+1.05%+1.15%+28.12%+103.30% 505B
+0.73%+2.45%+54.26%+66.47% 384B
+4.40%-0.21%+69.70%+43.10% 348B
+2.38%+2.65%+34.31%+56.33% 294B
+2.26%+0.55%+3.92%+27.74% 264B
+1.56%+2.29%+56.81%+73.84% 244B
+1.48%+2.56%+36.05%+107.30% 197B
Average +2.28%+1.84%+43.21%+82.53% 403.82B
Weighted average by Cap. +3.07%+1.50%+49.37%+92.58%

Financials

2027 *2028 *
Net sales 58.23B 611M 548M 505M 457M 855M 869M 6.03B 2.4B 30.47B 2.29B 2.25B 96.52B 69.12B 726M 650M 600M 543M 1.01B 1.03B 7.16B 2.85B 36.18B 2.72B 2.67B 115B
Net income 6.28B 65.92M 59.04M 54.47M 49.29M 92.18M 93.66M 650M 259M 3.29B 247M 242M 10.41B 8.8B 92.39M 82.75M 76.34M 69.09M 129M 131M 911M 363M 4.6B 347M 339M 14.58B
Net Debt - -
Projected Income Statement - Annual - Strides Pharma Science Limited
Logo Strides Pharma Science Limited
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
Employees
3,535
Date Price Change Volume
29/10/26 ₹1,097.50 +1.10% 203,597
28/10/26 ₹1,085.60 -0.70% 396,045
27/10/26 ₹1,093.30 +5.83% 787,306
26/10/26 ₹1,033.10 +1.80% 281,520
23/10/26 ₹1,014.80 +1.64% 312,385
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Strides Pharma Science Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1,097.50INR
Average target price
1,338.67INR
Spread / Average Target
+21.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Strides Pharma Science Limited
  1. Stock Market
  2. Stocks
  3. STAR Stock